TN2010000120A1 - Galenical formulations of organic compounds - Google Patents
Galenical formulations of organic compoundsInfo
- Publication number
- TN2010000120A1 TN2010000120A1 TNP2010000120A TN2010000120A TN2010000120A1 TN 2010000120 A1 TN2010000120 A1 TN 2010000120A1 TN P2010000120 A TNP2010000120 A TN P2010000120A TN 2010000120 A TN2010000120 A TN 2010000120A TN 2010000120 A1 TN2010000120 A1 TN 2010000120A1
- Authority
- TN
- Tunisia
- Prior art keywords
- organic compounds
- dosage form
- oral dosage
- galenical formulations
- present
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000002894 organic compounds Chemical class 0.000 title 1
- 239000006186 oral dosage form Substances 0.000 abstract 3
- 239000007787 solid Substances 0.000 abstract 2
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229960004601 aliskiren Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97589407P | 2007-09-28 | 2007-09-28 | |
PCT/EP2008/062769 WO2009040373A2 (fr) | 2007-09-28 | 2008-09-24 | Formulations galéniques de composés organiques |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2010000120A1 true TN2010000120A1 (en) | 2011-09-26 |
Family
ID=40377181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2010000120A TN2010000120A1 (en) | 2007-09-28 | 2010-03-19 | Galenical formulations of organic compounds |
Country Status (22)
Country | Link |
---|---|
US (1) | US20110033533A1 (fr) |
EP (2) | EP2205232A2 (fr) |
JP (1) | JP5378384B2 (fr) |
KR (1) | KR20100076996A (fr) |
CN (1) | CN101808630A (fr) |
AR (1) | AR068539A1 (fr) |
AU (1) | AU2008303504C1 (fr) |
BR (1) | BRPI0817586A2 (fr) |
CA (1) | CA2697229A1 (fr) |
CL (1) | CL2008002828A1 (fr) |
CO (1) | CO6270216A2 (fr) |
GT (1) | GT201000064A (fr) |
MA (1) | MA31768B1 (fr) |
MX (1) | MX2010003260A (fr) |
MY (1) | MY148266A (fr) |
NZ (1) | NZ584005A (fr) |
PE (1) | PE20091203A1 (fr) |
RU (1) | RU2483718C2 (fr) |
TN (1) | TN2010000120A1 (fr) |
TW (1) | TWI436760B (fr) |
WO (1) | WO2009040373A2 (fr) |
ZA (1) | ZA201001144B (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2724746A1 (fr) * | 2008-05-23 | 2009-11-26 | Teva Pharmaceuticals Industries Ltd. | Monofumarate d'aliskirene et procedes de preparation associes |
TW201136582A (en) | 2010-03-16 | 2011-11-01 | Novartis Ag | Improved pharmaceutical compositions of aliskiren and methods of delivery |
TR201002256A1 (tr) | 2010-03-24 | 2011-10-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Stabil aliskiren formülasyonları |
EP2382969A1 (fr) | 2010-04-30 | 2011-11-02 | Sanovel Ilac Sanayi ve Ticaret A.S. | Formulations d'Aliskiren multi-couches |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
US6521647B2 (en) * | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
AU2002226365A1 (en) * | 2000-12-01 | 2002-06-11 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
RU2183116C1 (ru) * | 2001-07-10 | 2002-06-10 | Жаров Олег Владимирович | Фармацевтическая композиция, обладающая болеутоляющим, противовоспалительным, антипиретическим и спазмолитическим действием |
US20040266743A1 (en) * | 2003-05-09 | 2004-12-30 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and a renin inhibitor |
AR048431A1 (es) * | 2004-03-17 | 2006-04-26 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
US20050220865A1 (en) * | 2004-04-02 | 2005-10-06 | Koleng John J | Compressed composition comprising magnesium salt |
MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
CA2605771A1 (fr) * | 2005-04-27 | 2006-11-02 | Novartis Ag | Methodes de traitement de l'atherosclerose |
WO2007056324A2 (fr) * | 2005-11-08 | 2007-05-18 | Novartis Ag | Combinaison de composes organiques pour le traitement des maladies cardiovasculaires |
TW200804241A (en) * | 2006-02-24 | 2008-01-16 | Novartis Ag | New salt |
GB0605688D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
EP1891937A1 (fr) * | 2006-08-25 | 2008-02-27 | Novartis AG | Formulations galéniques de l'aliskiren |
US20100130616A1 (en) * | 2006-11-09 | 2010-05-27 | Novartis Ag | Salt of aliskiren with orotic acid |
EP1972335A1 (fr) * | 2007-03-23 | 2008-09-24 | Krka | Formes de dosage solide comportant de l'aliskiren et ses sels pharmaceutiques acceptables |
US20100209480A1 (en) * | 2007-09-28 | 2010-08-19 | Ralf Altenburger | Galenical formulations of organic compounds |
-
2008
- 2008-09-24 EP EP08804674A patent/EP2205232A2/fr not_active Withdrawn
- 2008-09-24 CN CN200880108854A patent/CN101808630A/zh active Pending
- 2008-09-24 EP EP12188621A patent/EP2548553A1/fr not_active Withdrawn
- 2008-09-24 CA CA2697229A patent/CA2697229A1/fr not_active Abandoned
- 2008-09-24 PE PE2008001663A patent/PE20091203A1/es not_active Application Discontinuation
- 2008-09-24 MX MX2010003260A patent/MX2010003260A/es active IP Right Grant
- 2008-09-24 MY MYPI2010000722A patent/MY148266A/en unknown
- 2008-09-24 AR ARP080104136A patent/AR068539A1/es unknown
- 2008-09-24 KR KR1020107009195A patent/KR20100076996A/ko not_active Application Discontinuation
- 2008-09-24 CL CL2008002828A patent/CL2008002828A1/es unknown
- 2008-09-24 RU RU2010116530/15A patent/RU2483718C2/ru not_active IP Right Cessation
- 2008-09-24 TW TW097136655A patent/TWI436760B/zh not_active IP Right Cessation
- 2008-09-24 US US12/679,088 patent/US20110033533A1/en not_active Abandoned
- 2008-09-24 JP JP2010526278A patent/JP5378384B2/ja not_active Expired - Fee Related
- 2008-09-24 NZ NZ584005A patent/NZ584005A/xx not_active IP Right Cessation
- 2008-09-24 BR BRPI0817586 patent/BRPI0817586A2/pt not_active IP Right Cessation
- 2008-09-24 AU AU2008303504A patent/AU2008303504C1/en not_active Ceased
- 2008-09-24 WO PCT/EP2008/062769 patent/WO2009040373A2/fr active Application Filing
-
2010
- 2010-02-17 ZA ZA2010/01144A patent/ZA201001144B/en unknown
- 2010-03-17 GT GT201000064A patent/GT201000064A/es unknown
- 2010-03-19 TN TNP2010000120A patent/TN2010000120A1/fr unknown
- 2010-04-08 MA MA32758A patent/MA31768B1/fr unknown
- 2010-04-19 CO CO10045478A patent/CO6270216A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200922546A (en) | 2009-06-01 |
MX2010003260A (es) | 2010-04-29 |
MA31768B1 (fr) | 2010-10-01 |
JP5378384B2 (ja) | 2013-12-25 |
AU2008303504B2 (en) | 2012-03-22 |
BRPI0817586A2 (pt) | 2015-03-31 |
US20110033533A1 (en) | 2011-02-10 |
AR068539A1 (es) | 2009-11-18 |
PE20091203A1 (es) | 2009-09-11 |
KR20100076996A (ko) | 2010-07-06 |
NZ584005A (en) | 2012-08-31 |
TWI436760B (zh) | 2014-05-11 |
CN101808630A (zh) | 2010-08-18 |
CA2697229A1 (fr) | 2009-04-02 |
RU2483718C2 (ru) | 2013-06-10 |
WO2009040373A2 (fr) | 2009-04-02 |
WO2009040373A3 (fr) | 2009-08-20 |
MY148266A (en) | 2013-03-29 |
AU2008303504C1 (en) | 2013-05-16 |
ZA201001144B (en) | 2011-12-28 |
EP2548553A1 (fr) | 2013-01-23 |
JP2010540489A (ja) | 2010-12-24 |
CO6270216A2 (es) | 2011-04-20 |
AU2008303504A1 (en) | 2009-04-02 |
EP2205232A2 (fr) | 2010-07-14 |
GT201000064A (es) | 2012-03-30 |
RU2010116530A (ru) | 2011-11-10 |
CL2008002828A1 (es) | 2009-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY144477A (en) | Galenic formulations of organic compounds | |
NZ600231A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
WO2008023016A3 (fr) | Formulations galéniques de composés organiques | |
GEP20125566B (en) | Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | |
NZ584686A (en) | Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate | |
UA105766C2 (uk) | Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин | |
HK1147202A1 (en) | Orally disintegrated dosage form | |
GB2465897A (en) | Respiratory disease treatment | |
TN2010000135A1 (en) | Galenical formulations of organic compounds | |
MX354423B (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
UA96622C2 (ru) | Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования | |
MX2011008910A (es) | Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson. | |
WO2010097243A3 (fr) | Procédé de fabrication de formes posologiques orales de solifénacine et de ses sels pharmaceutiquement acceptables | |
WO2009038412A3 (fr) | Composés inhibiteurs de la béta-sécrétase | |
TN2010000120A1 (en) | Galenical formulations of organic compounds | |
TW200640465A (en) | New pharmaceutically active compounds for the treatment of respiratory diseases | |
NZ611438A (en) | Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs | |
MA32722B1 (fr) | Formulation galénique renfermant de l'aliskirène et procédé associé de préparation par granulation par fusion-extrusion | |
NZ587941A (en) | Methods to inhibit tumor cell growth by using lansoprazole | |
MX2012002209A (es) | Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos. | |
WO2012060594A3 (fr) | Composition anti-inflammatoire contenant un composé thiourée et un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif | |
NZ614975A (en) | Ectoparasiticidal methods and formulations | |
WO2011149206A3 (fr) | Composition pharmaceutique contenant du chlorhydrate de nébivolol cristallin et procédé pour sa préparation | |
TR200802061A2 (tr) | Yüksek oranda aktif madde içeren farmasötlk formülasyon. | |
TN2011000107A1 (en) | Galenical formulation comprising aliskiren and process for its preparation by melt extrusion granulation |